Danish Construction Stock News

The market rallied behind Trifork Group AG's ( CPH:TRIFOR ) stock, leading do a rise in the share price after its...

Wondering if Genmab shares are truly worth their current price? Here is what savvy investors should know about its value. The stock has gained 25.3% year-to-date and is up 21.6% over the past year. However, it did pull back by 6.1% in the last month, highlighting both growth potential and possible shifting risk perceptions. Genmab recently saw renewed investor interest after positive updates on its cancer drug pipeline and new partnership announcements. These factors have fueled both...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

In recent days, several Gubra board members, including co-founder Jacob Jelsing, Chairman Monika Lessl, and CEO Markus Rohrwild, purchased company shares on NASDAQ Copenhagen, with total acquisitions exceeding DKK 16.6 million. This wave of insider buying was disclosed in official announcements and often signals heightened confidence in Gubra’s outlook among its leadership. We'll examine how these substantial insider share purchases may impact perceptions of Gubra’s resilience amid shifting...

As European markets face a pullback amid concerns over artificial intelligence stock valuations, major indices like the STOXX Europe 600 and Germany's DAX have seen declines. In this environment of cautious sentiment, identifying undervalued stocks can provide opportunities for investors seeking potential value plays.

Most people feel a little frustrated if a stock they own goes down in price. But sometimes broader market conditions...

TORM (CPSE:TRMD A) shares have delivered a 25% gain over the past 3 months, catching the attention of investors interested in the energy sector. The stock’s performance makes it a common conversation starter for those tracking Nordic shipping companies. See our latest analysis for TORM. TORM’s recent 24.7% share price return over the last 90 days stands out against an otherwise steady year, suggesting that momentum may be building again after a relatively muted period. While the 12-month...

It's been a mediocre week for GN Store Nord A/S ( CPH:GN ) shareholders, with the stock dropping 10% to kr.102 in the...

Shareholders might have noticed that Solar A/S ( CPH:SOLAR B ) filed its quarterly result this time last week. The...

A.P. Møller - Mærsk A/S ( CPH:MAERSK B ) just released its latest third-quarter results and things are looking bullish...

Key Insights Given the large stake in the stock by institutions, DSV's stock price might be vulnerable to their trading...

Ørsted (CPSE:ORSTED) shares have seen varied performance lately, with modest gains this week but losses over the past month and three months. Investors might be weighing the company’s fundamentals in comparison to recent market trends. See our latest analysis for Ørsted. Looking at the bigger picture, Ørsted’s share price has struggled, with short-term gains doing little to offset a year-to-date decline of 65%. Its one-year total shareholder return is down 44%. This fading momentum may signal...

A.P. Møller - Mærsk A/S announced third quarter 2025 results, reporting sales of US$14.21 billion and net income of US$1.05 billion, both down from the same period last year. Over the first nine months of 2025, sales held relatively steady year-on-year, but net income and earnings per share fell markedly, highlighting ongoing pressures on profitability. We’ll examine how the recent earnings decline could impact Maersk’s longer-term outlook, especially amid challenging global freight market...

Coloplast (CPSE:COLO B) is projecting healthy momentum, with earnings forecast to grow at 15.8% per year, outpacing the Danish market's 3.7% average. Revenue is also expected to climb at 6.9% annually, ahead of the market's 5% rate. Despite these positive forecasts, the company’s net profit margin has contracted to 13% from 18.7% last year. Five-year earnings growth has averaged just 0.03% per year, with earnings declining over the past year. Investors are eyeing Coloplast’s above-market...

Pandora (CPSE:PNDORA) shares have experienced a noticeable slide over the past month, falling nearly 7%. Despite the quieter news cycle, investors appear to be reassessing the company's current valuation and future growth prospects. See our latest analysis for Pandora. Pandora’s share price stumble this month reflects a cautious shift in investor sentiment, with momentum having faded since the strong gains of prior years. After a standout 72.4% total shareholder return over the past three...

Wondering if Bavarian Nordic is a hidden gem or simply riding the latest biotech wave? Let's dig in and see if the stock is living up to its reputation. Bavarian Nordic shares have seen a solid 18.2% jump year-to-date and are up 13.6% over the past year, but there was a slight dip of 0.6% just last week. Recent headlines highlight the company's expanding role in vaccine development, with positive investor sentiment driven by new partnerships and regulatory milestones. These developments have...

Curious if Novozymes is worth a closer look, whether you are already holding shares or just valuation-savvy? Let’s get straight to what matters for investors weighing the company’s true worth. The share price has slipped by 2.5% over the past week and is down 9.2% in the past year, hinting at shifting sentiment and fresh questions around growth potential. Recent headlines around Novozymes' strategic initiatives in sustainable bio-solutions and its ongoing integration efforts with Chr. Hansen...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Thinking about whether FLSmidth stock is a bargain, or perhaps getting a bit pricey? Let’s take a closer look at what’s really going on beneath the surface. Over the last year, FLSmidth’s share price has surged 39.4%, and it’s up a remarkable 34.5% year-to-date, even after a recent dip of 5.2% in the last week. One driver for these moves has been ongoing sector consolidation news and recent project wins, fueling optimism around future growth and improved margins. In the same period, market...

There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...

Wondering if Danske Bank is a hidden gem or already priced to perfection? Let's dig into what the numbers and recent market action are signaling about its current value. Danske Bank’s stock has been on a tear, surging 6.3% in the past week and up 42.0% year-to-date, with an impressive 52.7% gain over the last 12 months. Recent news highlights Danske Bank’s ongoing digital transformation and several strategic partnerships, both of which have caught investor attention. Industry talk about...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

The Netcompany Group A/S ( CPH:NETC ) share price has done very well over the last month, posting an excellent gain of...